Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
8 participants
INTERVENTIONAL
2021-01-15
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
NCT02890641
Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
NCT06448663
Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients
NCT03220256
Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits
NCT00851331
The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients
NCT03403907
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm group
Galactose supplementation
D-Galactose
Galactose supplementation, once per day, up to 1.5g/kg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-Galactose
Galactose supplementation, once per day, up to 1.5g/kg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Epilepsy refractoriness or ongoing epileptiform activity at EEG.
Exclusion Criteria
2 Years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Ruber Internacional
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angel Aledo-Serrano
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angel Aledo-Serrano, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Ruber Internacional
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Ruber Internacional
Madrid, Madrid, Comunidad de, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEUROLOGIAHRI-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.